Additionally, in our cohort, patients with an early onset of lymphopenia (<4 months after start of ICI therapy) showed a trend towards a shorter mean OS compared to patients with a delayed (4–12 months after start of ICI therapy) or a late onset (>12 months after start of ICI therapy) of lymphopenia, but the groups were small.
← all excerpts
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma.
1
—
—